These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 12131334)
41. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Abrams P; Cardozo L; Chapple C; Serdarevic D; Hargreaves K; Khullar V; Int J Urol; 2006 Jun; 13(6):692-8. PubMed ID: 16834644 [TBL] [Abstract][Full Text] [Related]
42. [Therapeutic effects of intrarectal administration of oxybutynin]. Radziszewski P; Borkowski A Wiad Lek; 2002; 55(11-12):691-8. PubMed ID: 12715351 [TBL] [Abstract][Full Text] [Related]
43. Case 7: the addled nonagenarian. Shader RI; Oesterheld JR J Clin Psychopharmacol; 1995 Oct; 15(5):378. PubMed ID: 8830074 [No Abstract] [Full Text] [Related]
44. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion. Oki T; Toma-Okura A; Yamada S J Pharmacol Exp Ther; 2006 Mar; 316(3):1137-45. PubMed ID: 16282521 [TBL] [Abstract][Full Text] [Related]
45. This month in investigative urology: new insights into the clinical value of oxybutynin. Chai TC J Urol; 1998 Sep; 160(3 Pt 1):644. PubMed ID: 9720514 [No Abstract] [Full Text] [Related]
46. [Use of oxybutynin hydrochloride in the treatment of primary dysmenorrhea]. Piato S; Delascio D Matern Infanc (Sao Paulo); 1968; 27(2):95-101. PubMed ID: 5746834 [No Abstract] [Full Text] [Related]
51. Oxybutynin-induced reflux esophagitis. Lee M; Sharifi R DICP; 1990 Jun; 24(6):583-5. PubMed ID: 2360335 [TBL] [Abstract][Full Text] [Related]
52. Oxybutynin: a new drug with analgesic and anticholinergic properties. Diokno AC; Lapides J J Urol; 1972 Aug; 108(2):307-9. PubMed ID: 5047425 [No Abstract] [Full Text] [Related]
53. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice. Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647 [TBL] [Abstract][Full Text] [Related]
54. Alum irrigation in the treatment of severe haemorrhage from the bladder. Nurmi M; Puntala P; Torniainen K Ann Chir Gynaecol; 1987; 76(3):173-5. PubMed ID: 3674728 [TBL] [Abstract][Full Text] [Related]
55. Epistaxis as a side effect of oxybutynin in children: report of two cases. Batista JE; Caffaratti J; Garat JM Neurourol Urodyn; 1994; 13(1):85-6. PubMed ID: 8156079 [No Abstract] [Full Text] [Related]
56. Comparison between oxybutynin, functional electrical stimulation and pelvic floor training for treatment of detrusor overactivity in women: a review. Arruda RM; Castro R; Sartori M; Girão MJ Curr Opin Obstet Gynecol; 2009 Oct; 21(5):412-4. PubMed ID: 19593131 [TBL] [Abstract][Full Text] [Related]
57. Transdermal oxybutynin (oxytrol) for urinary incontinence. Dull P Am Fam Physician; 2004 Dec; 70(12):2351-2. PubMed ID: 15617300 [No Abstract] [Full Text] [Related]
58. Transdermal oxybutynin for overactive bladder. Davila GW; Starkman JS; Dmochowski RR Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381 [TBL] [Abstract][Full Text] [Related]
59. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study. Stöhrer M; Mürtz G; Kramer G; Schnabel F; Arnold EP; Wyndaele JJ; Eur Urol; 2007 Jan; 51(1):235-42. PubMed ID: 16698176 [TBL] [Abstract][Full Text] [Related]
60. Association between oxybutynin and neuropsychiatric adverse effects not confirmed in daily practice. Movig KL; Egberts AC; Lenderink AW; Leufkens HG J Am Geriatr Soc; 2001 Feb; 49(2):234-5. PubMed ID: 11207885 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]